Although limited trials of CDK9 inhibitors have not yet established clear single-agent activity in MM [17, 45], it is possible that sub-optimal scheduling or pharmacokinetics may have limited the efficacy of such agents to date [46]. The gene discussed is CDK9; the disease is Miyoshi myopathy.